Prions: Protein Aggregation and Infectious Diseases - Physiological ...

1144 ADRIANO AGUZZI AND ANNA MARIA CALELLA
169. Gabizon R, McKinley MP, Prusiner SB. Purified prion proteins
and scrapie infectivity copartition into liposomes. Proc Natl Acad
Sci USA 84: 4017–4021, 1987.
170. Gabriel JM, Oesch B, Kretzschmar H, Scott M, Prusiner SB.
Molecular cloning of a candidate chicken prion protein. Proc Natl
Acad Sci USA 89: 9097–9101, 1992.
171. Gajdusek D, Zigas V. Clinical, pathological and epidemiological
study of an acute progressive degenerative disease of the central
nervous system among natives of the eastern higlands of New
Guinea. Am J Med 26: 442–469, 1959.
172. Gajdusek DC. Unconventional viruses and the origin and disappearance
of kuru. Science 197: 943–960, 1977.
173. Gajdusek DC, Zigas V. Degenerative disease of the central nervous
system in New Guinea: the endemic occurrence of “kuru” in
the native population. N Engl J Med 257: 974–978, 1957.
174. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and
familial CJD: classification and characterisation. Br Med Bull 66:
213–239, 2003.
175. Gambetti P, Parchi P, Petersen RB, Chen SG, Lugaresi E.
Fatal familial insomnia and familial Creutzfeldt-Jakob disease: clinical,
pathological and molecular features. Brain Pathol 5: 43–51,
1995.
176. Gasset M, Baldwin MA, Fletterick RJ, Prusiner SB. Perturbation
of the secondary structure of the scrapie prion protein under
conditions that alter infectivity. Proc Natl Acad Sci USA 90: 1–5,
1993.
177. Genoud N, Behrens A, Miele G, Robay D, Heppner FL,
Freigang S, Aguzzi A. Disruption of Doppel prevents neurodegeneration
in mice with extensive Prnp deletions. Proc Natl Acad
Sci USA 101: 4198–4203, 2004.
178. Genoud N, Ott D, Braun N, Prinz M, Schwarz P, Suter U,
Trono D, Aguzzi A. Antiprion prophylaxis by gene transfer of a
soluble prion antagonist. Am J Pathol 172: 1287–1296, 2008.
179. Gerstmann J, Sträussler E, Scheinker I. über eine eigenartige
hereditär-familiäre Erkrankung des Zentralnervensystems. Zugleich
ein Beitrag zur Frage des vorzeitigen lokalen Alterns Z
Neurol 154: 736–762, 1936.
180. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Assessment
of the prevalence of vCJD through testing tonsils and appendices
for abnormal prion protein. Proc Biol Sci 267: 23–29, 2000.
181. Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson
RM. Estimation of the number of people incubating variant
CJD. Lancet 352: 1353–1354, 1998.
182. Gibbons RA, Hunter GD. Nature of the scrapie agent. Nature 215:
1041–1043, 1967.
183. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic
prion protein in sporadic Creutzfeldt-Jakob disease. N Engl
J Med 349: 1812–1820, 2003.
184. Glatzel M, Aguzzi A. PrP(C) expression in the peripheral nervous
system is a determinant of prion neuroinvasion. J Gen Virol 81:
2813–2821, 2000.
185. Glatzel M, Aguzzi A. The shifting biology of prions. Brain Res
Brain Res Rev 36: 241–248, 2001.
186. Glatzel M, Heppner FL, Albers KM, Aguzzi A. Sympathetic
innervation of lymphoreticular organs is rate limiting for prion
neuroinvasion. Neuron 31: 25–34, 2001.
187. Glatzel M, Ott PM, Lindner T, Gebbers JO, Gmur A, Wuest W,
Huber G, Moch H, Podvinec M, Stamm B, Aguzzi A. Human
prion diseases: epidemiology and integrated risk assessment. Lancet
Neurol 2: 757–763, 2003.
188. Glaysher BR, Mabbott NA. Role of the draining lymph node in
scrapie agent transmission from the skin. Immunol Lett 109: 64–71,
2007.
189. Glaysher BR, Mabbott NA. Role of the GALT in scrapie agent
neuroinvasion from the intestine. J Immunol 178: 3757–3766, 2007.
190. Glockshuber R, Hornemann S, Billeter M, Riek R, Wider G,
Wuthrich K. Prion protein structural features indicate possible
relations to signal peptidases. FEBS Lett 426: 291–296, 1998.
191. Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments
and autoimmune disease. Nat Rev Immunol 3:
642–655, 2003.
192. Gommerman JL, Mackay F, Donskoy E, Meier W, Martin P,
Browning JL. Manipulation of lymphoid microenvironments in
Physiol Rev VOL 89 OCTOBER 2009 www.prv.org
nonhuman primates by an inhibitor of the lymphotoxin pathway.
J Clin Invest 110: 1359–1369, 2002.
193. Goni F, Prelli F, Schreiber F, Scholtzova H, Chung E, Kascsak
R, Brown DR, Sigurdsson EM, Chabalgoity JA, Wisniewski T.
High titers of mucosal and systemic anti-PrP antibodies abrogate
oral prion infection in mucosal-vaccinated mice. Neuroscience 153:
679–686, 2008.
194. Gordon WS. Advances in veterinary research. Vet Res 58: 516–520,
1946.
195. Gorodinsky A, Harris DA. Glycolipid-anchored proteins in neuroblastoma
cells form detergent-resistant complexes without
caveolin. J Cell Biol 129: 619–627, 1995.
196. Green KM, Castilla J, Seward TS, Napier DL, Jewell JE, Soto
C, Telling GC. Accelerated high fidelity prion amplification within
and across prion species barriers. PLoS Pathog 4: e1000139, 2008.
197. Griffith JS. Self-replication and scrapie. Nature 215: 1043–1044,
1967.
198. Haik S, Faucheux BA, Sazdovitch V, Privat N, Kemeny JL,
Perret-Liaudet A, Hauw JJ. The sympathetic nervous system is
involved in variant Creutzfeldt-Jakob disease. Nat Med 9: 1121–
1122, 2003.
199. Hainfellner JA, Brantner Inthaler S, Cervenakova L, Brown
P, Kitamoto T, Tateishi J, Diringer H, Liberski PP, Regele H,
Feucht M. The original Gerstmann-Straussler-Scheinker family of
Austria: divergent clinicopathological phenotypes but constant PrP
genotype. Brain Pathol 5: 201–211, 1995.
200. Hamir AN, Kunkle RA, Miller JM, Hall SM. Abnormal prion
protein in ectopic lymphoid tissue in a kidney of an asymptomatic
white-tailed deer experimentally inoculated with the agent of
chronic wasting disease. Vet Pathol 43: 367–369, 2006.
201. Haraguchi T, Fisher S, Olofsson S, Endo T, Groth D, Tarentino
A, Borchelt DR, Teplow D, Hood L, Burlingame A.
Asparagine-linked glycosylation of the scrapie and cellular prion
proteins. Arch Biochem Biophys 274: 1–13, 1989.
202. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science
297: 353–356, 2002.
203. Healy DL, Evans J. Creutzfeldt-Jakob disease after pituitary gonadotrophins.
BMJ 307: 517–518, 1993.
204. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P,
Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR. A transmembrane
form of the prion protein in neurodegenerative disease.
Science 279: 827–834, 1998.
205. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB,
Lingappa VR. Transmissible and genetic prion diseases share a
common pathway of neurodegeneration Nature 402: 822–826, 1999.
206. Heikenwalder M, Federau C, von Boehmer L, Schwarz P,
Wagner M, Zeller N, Haybaeck J, Prinz M, Becher B, Aguzzi A.
Germinal center B cells are dispensable in prion transport and
neuroinvasion. J Neuroimmunol 192: 113–123, 2007.
207. Heikenwalder M, Julius C, Aguzzi A. Prions and peripheral
nerves: a deadly rendezvous. J Neurosci Res 85: 2714–2725, 2007.
208. Heikenwalder M, Kurrer MO, Margalith I, Kranich J, Zeller N,
Haybaeck J, Polymenidou M, Matter M, Bremer J, Jackson
WS, Lindquist S, Sigurdson CJ, Aguzzi A. Lymphotoxin-dependent
prion replication in inflammatory stromal cells of granulomas.
Immunity 29: 998–1008, 2008.
209. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner
H, Akira S, Zinkernagel R, Aguzzi A. Lymphoid follicle
destruction and immunosuppression after repeated CpG oligodeoxynucleotide
administration. Nat Med 10: 187–192, 2004.
210. Heikenwalder M, Zeller N, Seeger H, Prinz M, Klohn PC,
Schwarz P, Ruddle NH, Weissmann C, Aguzzi A. Chronic lymphocytic
inflammation specifies the organ tropism of prions. Science
307: 1107–1110, 2005.
211. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H,
Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A
Toll-like receptor recognizes bacterial DNA. Nature 408: 740–745,
2000.
212. Heppner FL, Christ AD, Klein MA, Prinz M, Fried M, Kraehenbuhl
JP, Aguzzi A. Transepithelial prion transport by M cells.
Nat Med 7: 976–977, 2001.